We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Glofitamab plus R‐CHOP or polatuzumab vedotin‐R‐CHP is deliverable with high overall response in patients ≤65 years of age with high‐risk DLBCL: Interim analysis of COALITION.
- Authors
Minson, A.; Verner, E.; Giri, P.; Wong, S. M.; Ratnasingam, S.; Butler, J.; Janowski, W.; Ku, M.; Cheah, C. Y.; Hertzberg, M.; Herbert, K.; Hamad, N.; Yannakou, C. K.; Neeson, P.; Saghebi, J.; Blombery, P.; Robertson, M.; Lau, L. S.; Xie, J.; Seymour, J. F.
- Abstract
B Results: b 47 patients have received >=1 dose of study treatment at Nov 1, 2022 (25 Arm A, 22 Arm B). 42 (89%) have de novo DLBCL and 5 (11%) have transformed indolent lymphoma. Glofitamab plus R-CHOP or polatuzumab vedotin-R-CHP is deliverable with high overall response in patients <=65 years of age with high-risk DLBCL: Interim analysis of COALITION B Background: b Improved treatments are needed for patients (pts) with high-risk (HR) DLBCL.
- Subjects
ANTINEOPLASTIC combined chemotherapy protocols; DIFFUSE large B-cell lymphomas; TERMINATION of treatment; COALITIONS; BISPECIFIC antibodies
- Publication
Hematological Oncology, 2023, Vol 41, p421
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.3164_309